Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
In subjects aged 18 to 59 years for the ID influenza vaccine 9 µg and in subjects aged 60 years or older for the ID influenza vaccine 15 µg: 1) To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the ID influenza vaccine Northern Hemisphere (NH) 2009-2010 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96. 2) To describe the safety of the corresponding strength of the ID influenza vaccine, NH 2009-2010 formulation.
Critère d'inclusion
- Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intradermal route